145022-92-0
Chemical Structure
Tauro-β-muricholic acid sodium
Synonym(s): T-βMCA sodium
- CAS No.: 145022-92-0
- Formula:C26H44NNaO7S
- Molecular Weight:537.68
IUPAC Name: sodium 2-((R)-4-((3R,5R,6S,7R,8S,9S,10R,13R,14S,17R)-3,6,7-trihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanamido)ethane-1-sulfonate
InChIKey: NYXROOLWUZIWRB-GPHZYVDLSA-M
SMILES: C[C@@]([C@]1([H])[C@H](O)[C@@H]2O)(CC[C@@H](O)C1)[C@]3([H])[C@]2([H])[C@@](CC[C@]4([H])[C@H](C)CCC(NCCS(=O)(O[Na])=O)=O)([H])[C@]4(C)CC3
Biological Activity: Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tauro-β-muricholic acid sodium | 99.54% | Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tauro-β-muricholic acid-d4 sodium | Tauro-β-muricholic acid-d4 (sodium) is the deuterium labeled Tauro-β-muricholic acid sodium. Tauro-β-muricholic Acid sodium (T-βMCA sodium), a endogenous metabolite, is a competitive and reversible farnesoid X receptor (FXR) antagonist, with an IC50 of 40 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Sayin SI, et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013 Feb 5;17(2):225-35. [Content Brief]
- [2]. Wahlström A, et al. Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. J Lipid Res. 2017 Feb;58(2):412-419. [Content Brief]
- [3]. Fu T, et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation. Cell. 2019 Feb 21;176(5):1098-1112.e18. [Content Brief]
